This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1980;4(1):5-10.

doi: 10.1007/BF00255451.

The clinical evaluation of analogs--III. Anthracyclines

PMID: 7363403
DOI: 10.1007/BF00255451

The clinical evaluation of analogs--III. Anthracyclines

S K Carter. Cancer Chemother Pharmacol. 1980.

. 1980;4(1):5-10.

doi: 10.1007/BF00255451.

Author

PMID: 7363403
DOI: 10.1007/BF00255451

No abstract available

PubMed Disclaimer

Similar articles

New drug counters doxorubicin cardiotoxicity; not for use at start of chemotherapy.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 1995 Oct 1;52(19):2076. doi: 10.1093/ajhp/52.19.2076. Am J Health Syst Pharm. 1995. PMID: 8535936 No abstract available.
[THP-adriamycin: status of the clinical development of a new anthracycline in France].
Herait P. Herait P. Pathol Biol (Paris). 1990 Jan;38(1):64-8. Pathol Biol (Paris). 1990. PMID: 2308782 French.
Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L, Bramwell V, Moran LA. Seymour L, et al. Cancer Prev Control. 1999 Apr;3(2):145-59. Cancer Prev Control. 1999. PMID: 10474762
The anthracyclines: will we ever find a better doxorubicin?
Weiss RB. Weiss RB. Semin Oncol. 1992 Dec;19(6):670-86. Semin Oncol. 1992. PMID: 1462166 Review.
Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin.
Hurteloup P, Ganzina F. Hurteloup P, et al. Drugs Exp Clin Res. 1986;12(1-3):233-46. Drugs Exp Clin Res. 1986. PMID: 3525075 Review.

See all similar articles

Cited by

Uptake and retention of morpholinyl anthracyclines by adriamycin-sensitive and -resistant P388 cells.
Streeter DG, Johl JS, Gordon GR, Peters JH. Streeter DG, et al. Cancer Chemother Pharmacol. 1986;16(3):247-52. doi: 10.1007/BF00293986. Cancer Chemother Pharmacol. 1986. PMID: 3457646
Mitoxantrone: propensity for free radical formation and lipid peroxidation--implications for cardiotoxicity.
Novak RF, Kharasch ED. Novak RF, et al. Invest New Drugs. 1985;3(2):95-9. doi: 10.1007/BF00174155. Invest New Drugs. 1985. PMID: 2991163
Treatment of acute leukemia and malignant lymphoma with (2"R)-4'-O-tetrahydropyranyladriamycin.
Ohno R, Kimura K, Amaki I, Hirano M, Hoshino A, Ikeda Y, Kimura I, Kobayashi M, Konno K, Majima H, et al. Ohno R, et al. Cancer Chemother Pharmacol. 1987;20(3):230-4. doi: 10.1007/BF00570491. Cancer Chemother Pharmacol. 1987. PMID: 3315282 Clinical Trial.
Phase I study of 4-demethoxydaunorubicin.
Bonfante V, Ferrari L, Villani F, Bonadonna G. Bonfante V, et al. Invest New Drugs. 1983;1(2):161-8. doi: 10.1007/BF00172075. Invest New Drugs. 1983. PMID: 6590530
Effect of amrinone on anthracycline-induced lethal and cardiac toxicity in mice and rats.
Villani F, Manzotti C, Mella M, Monti E, Savi G, Zunino F. Villani F, et al. Med Oncol Tumor Pharmacother. 1990;7(4):227-32. doi: 10.1007/BF02987100. Med Oncol Tumor Pharmacother. 1990. PMID: 2283890

See all "Cited by" articles

References

1. Ann Intern Med. 1978 Feb;88(2):168-75 - PubMed
1. Cancer Res. 1975 May;35(5):1354-64 - PubMed
1. Natl Cancer Inst Monogr. 1977 Mar;(45):75-80 - PubMed
1. Am J Surg Pathol. 1977 Mar;1(1):17-23 - PubMed
1. J Natl Cancer Inst. 1975 Dec;55(6):1265-74 - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information